Published date:
26/01/2023
Summary:
– Eligible adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who have received 2 or more systemic therapies will have long-term NHS access to this treatment –
26th JANUARY 2023, LONDON, UK – Gilead Sciences Ltd. and Kite, a Gilead company, today announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta® ▼ (axicabtagene ciloleucel; axi-cel) for routine commissioning on the NHS in England for the treatment of some adults with certain forms of lymphoma.
